Three to buy
(Shares) This credit-hire and legal services firm could be an “Aim star in the making”. After motoring accidents, Anexo steps in to provide replacement- hire vehicles. Bond Turner, its legal side, deals with personal injury and negligence claims, among others, and is currently involved in a class-action case against Volkswagen over vehicle emissions. Cashflow remained resilient during lockdown, enabling Anexo to continue paying a dividend. Analyst Andrew Simms of Arden thinks the shares could more than double from here thanks to a growing market share and more investment in the legal division. 132p
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
(Interactive Investor) This fishing-tackle supplier seems to be enjoying a pandemic boost as Britons turn to solitary, staycation-friendly sports. Revenue rose by 21% in the six months to 31 July despite the long closure of stores, with online traffic surging by 54%. Trading on the continent has also surged. There could be plenty of upside to come should this prove the start of a new trend. 60p
(The Mail on Sunday) This Vancouver-based mining company is cashing in on copper as prices trade around a two-year high. The group has one site in production, with one more due to come online soon, as well as four other prospects. The outlook for copper remains buoyant: governments are using infrastructure projects to stimulate the economy, supporting metals demand. On the supply side, Chilean and Peruvian output has also been constrained by the virus. The shares offer a way for British investors to play structural demand for the essential industrial metal. 65p
Three to sell
(Investors Chronicle) The UK housing market has been enjoying a surprise post-lockdown surge, but developers still expect lower prices later this year. This FTSE 250 housebuilder is among the most vulnerable because of its low operating margins. It remains exposed to the weak London market despite an ongoing effort to shift into regional, affordable housing. The shares are on a steep discount to forecast net asset value but bargain hunters should steer clear: two inventory write-downs since last November mark a worrying pattern. The short sellers are circling. 191p
(The Sunday Times) In spring 2019 co-founder Julian Dunkerton seized back control of this struggling clothing business with the help of activist investors, vowing to revamp a “misguided strategy”. Yet since then the stock has declined by three-quarters. The pandemic has depressed trading but the brand’s reliance on “department stores and city centres”, the result of over-expansion in the good times, raises longer-term questions. A £57.8m cash pile may provide a temporary buffer, but it won’t cover losses forever. Avoid the shares. 135p
(Motley Fool UK) Shares in this small biotech have soared 38-fold this year on hopes for its SNG001 treatment in the fight against Covid-19. Positive trials are encouraging but SNG001 still has further clinical hurdles to clear. The group may also be forced to turn to a pharmaceutical giant to scale up production and distribution. Potential partners are likely to demand a handsome cut of the revenue, so the valuation looks optimistic. Avoid. 231p
....and the rest
The Daily Telegraph
Improving the economy’s energy efficiency is becoming a key priority for governments and businesses. Industry-leading Irish insulation specialist Kingspan is well-placed to profit from the trend (€64.60). Catalytic converter maker Johnson Matthey will lose out from the rise of electric vehicles, but its investments in battery technology and hydrogen mean investors should not unplug just yet. Hold (2,295p). IP Group helps commercialise the innovations of British academics. Such early-stage investments are risky, but the portfolio is diversified and a 32% discount to net asset value is a further comfort. Hold (74p).
Buy into growth in the climate-friendly hydrogen business via industrial-gas specialist Linde ($248). The pandemic has not lifted all healthcare boats, with shares in surgical-products specialist Advanced Medical Solutions tumbling due to the widespread cancellation of elective surgeries. Yet sentiment should improve when business returns to normal, so take the opportunity to buy in (215p).
The Mail on Sunday
More people are cooking at home, generating new business for Cranswick, one of Britain’s leading pork producers. Dividends have increased annually for the past three decades. Shareholders may wish to cash in some of their profits but should keep “at least 50%” of their stake for the long term (3,768p).
Franco Manca pizza-owner Fulham Shore has had “two record weeks of trading” thanks to the restaurant-subsidy scheme and should emerge strongly from the crisis as rivals fall away. Buy (8.5p).
Nvidia becomes the fourth biggest company in the world - should you invest?
Chipmaker Nvidia is riding the AI wave, and has overtaken Alphabet and Amazon in terms of market capitalisation. Have new investors missed the boat, or will the share price soar higher?
By Ruth Emery Published
Savings market heats up as providers boost rates - should you switch now for a better return?
In a surprising twist, more and more banks are now hiking their savings rates. Is it a good time to move your money and grab a better rate?
By Vaishali Varu Published
Three high-quality global companies for growth
James Harries, a senior fund manager at STS Global Income & Growth Trust highlights three favourites.
By James Harries Published
Four high-quality stocks set for decades of dividend and earnings growth
Charles Luke, an investment manager for Murray Income Trust, highlights four favourite high-quality stocks.
By Charles Luke Published
Humana sees healthy growth in US healthcare
Humana is a major player in the American market and the stock’s valuation looks reasonable.
By Stephen Connolly Published
The nobbling of Britain’s nuclear energy sector
The UK once led the world in atomic power, but now it’s a has-been. The malaise is due to the left’s opposition to the sector and decisions taken by the Blair government.
By Max King Published
Five fantasy deals to hope for this year
From Amazon buying John Lewis to Warren Buffet taking on Unilever, these fantasy deals, mergers and acquisitions would improve the companies involved.
By Matthew Lynn Published
Stay safe: A financial crisis could still be around the corner
Investors were cheered by rate cuts, but Bill Bonner says don't get too excited…
By Bill Bonner Published
Why Laurent-Perrier could be a good buy
The market is overlooking Laurent-Perrier’s status as a top Champagne producer.
By Rupert Hargreaves Published
How fintech has gone mainstream
Once a niche sector, fintech went mainstream in 2023.
By David C. Stevenson Published